12:00 AM
 | 
Oct 29, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Denosumab: Phase III data

The double-blind, Japanese Phase III DIRECT trial in 1,262 patients with prevalent VFXs and low bone marrow density showed that denosumab met the primary endpoint of reducing the incidence of new or worsening VFXs over 2 years vs. placebo (3.6% vs. 10.3%, p=0.0001). On secondary endpoints, denosumab significantly reduced the incidence of new VFXs and major non-VFXs vs. placebo. Denosumab was well tolerated and adverse events were reported at similar rates between the denosumab...

Read the full 350 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >